Vivesto VIVE.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker VIVE.ST. It has been listed since 1 January 2005. In the fiscal year to 31 December 2022, it reported revenue of SEK 1.0m and a net loss of SEK 367.0m. At that date it held total assets of SEK 355.9m and shareholders' equity of SEK 325.4m.

Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2005-01-01. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. Its drugs portfolio comprises six candidates: Paclical, Doxophos, Docecal and OAS-19, which are implemented in human treatment, as well as Paccal Vet-CA1 and Doxophos Vet, introduced in cancer in dogs. The Company’s medicines are based on the patented XR-17 excipient, which forms micelles with water-soluble substances. Furthermore, It cooperates with Abbott Laboratories, Pharmasyntez, Nippon Zenyaku Kogyo and Medison Pharma. The firm is a parent of Oasmia Global Supplies AB and Oasmia Animal Health AB.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Peter ZonabendNon-Executive Chairman of the BoardSEK 756,000
• Mr. Erik KinnmanChief Executive OfficerSEK 5.0m
• Mr. Robert MaioranaActing Chief Financial Officer
• Ms. Johanna VostinChief Regulatory Officer
• Ms. Teresa ZafraChief Scientific Officer
• Ms. Hege HellstroemIndependent DirectorSEK 361,000
• Mr. Paul RyforsIndependent DirectorSEK 427,000
• Dr. Roger TellIndependent DirectorSEK 361,000

Overall

33

Environment

20

Social

23

Governance

56

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.